CML Pediatric ITK Response According to Molecular Identification at Diagnosis

This study is for children diagnosed with a blood cancer called chronic myeloid leukemia (CML). Researchers want to understand why some children respond well to targeted therapy (called TKIs — drugs that block abnormal signals driving the cancer) and others don't, by analyzing genetic material at the time of diagnosis. **You may be eligible if...** - You were 18 years old or younger at diagnosis - You have CML in its early (chronic) phase - Your leukemia has a specific genetic marker called Philadelphia chromosome with BCR::ABL1 transcripts e13a2 or e14a2 - You are being treated with a TKI as first-line therapy **You may NOT be eligible if...** - You were older than 18 at diagnosis - Your CML is in an advanced (accelerated or blast) phase - Your first treatment was something other than a TKI Talk to your doctor to see if this trial is right for you.